CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 151 enrolled
Drug / intervention
Duloxetine hydrochloridedrug
Likely dose
Duloxetine hydrochloride 30 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00437125
NCT00437125Phase 4Completed
CompareCT.gov

An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease

Eli Lilly and Company·interventional·Posted Feb 19, 2007·Updated Sep 8, 2010

In Brief

A Phase 4 clinical trial evaluating Duloxetine hydrochloride for Major Depressive Disorder and Idiopathic Parkinson Disease. Completed, enrolled 151 participants across 13 sites.

Detailed Summary

This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder, Idiopathic Parkinson Disease
CountriesItaly
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 19, 2007
Enrollment StartMar 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.4 years ago

Interventions

Duloxetine hydrochloridedrug

Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks